Summit, NJ (Press Release) –  Celgene Corpo­ra­tion (NASDAQ:CELG) today announced that the U.S. Food and Drug Admin­istration (FDA) has placed a partial clin­i­cal hold on five trials and a full clin­i­cal hold on one trial in the Celgene FUSION™ pro­gram. The trials are testing IMFINZI™ (durva­lumab), an anti-PD-L1 anti­body, in combi­nation with immuno­modulatory and chemo­therapy agents in blood cancers such as multiple myeloma, chronic lym­pho­cytic leukemia and lym­phoma.

The de­ci­sion by the FDA was based on risks identified in other trials for an anti-PD-1 anti­body, pem­bro­lizu­mab, in patients with multiple myeloma in …